Valuation: Apogee Therapeutics, Inc.

Market Cap 10.04B 8.8B 8.14B 7.48B 14.14B 969B 14.36B 97.15B 38.09B 473B 37.71B 36.89B 1,632B P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 9.06B 7.94B 7.34B 6.75B 12.76B 874B 12.96B 87.67B 34.37B 427B 34.03B 33.29B 1,473B EV / Sales 2026 *
997x
EV / Sales 2027 * 744x
Free-Float
94.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.11%
1 week+0.37%
Current month+1.07%
1 month+48.43%
3 months+45.50%
6 months+66.09%
Current year+77.73%
1 week 133.81
Extreme 133.81
134.32
1 month 132.45
Extreme 132.45
134.32
Current year 60.35
Extreme 60.35
134.32
1 year 34.34
Extreme 34.34
134.32
3 years 14.19
Extreme 14.19
134.32
5 years 14.19
Extreme 14.19
134.32
10 years 14.19
Extreme 14.19
134.32
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
14/07/26 Don

Chief Technology Officer

-8,000 0.0143%
10/07/26 Don

Chief Executive Officer

-75,046 0.1340%
01/07/26 Fiscal year

Chief Technology Officer

13,750 0.0246%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+0.37%+241.26%+555.99% 10.04B
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-3.47%+370.99%+567.62% 39.58B
-0.46%+3.98%+5.44%+60.79% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-6.91% - - 16.21B
-1.82%-1.91%+69.28%+112.51% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%-0.92%+15.77%-32.78% 13.02B
Average -1.33%-0.13%+82.80%+145.06% 25.37B
Weighted average by Cap. -1.37%-0.35%+82.91%+136.19%

Financials

2026 *2027 *
Net sales 9.09M 7.97M 7.37M 6.77M 12.8M 877M 13M 87.94M 34.48M 429M 34.14M 33.39M 1.48B 12.5M 10.95M 10.13M 9.31M 17.6M 1.21B 17.87M 121M 47.4M 589M 46.94M 45.91M 2.03B
Net income -318M -278M -257M -237M -447M -30.62B -454M -3.07B -1.2B -14.97B -1.19B -1.17B -51.59B -416M -365M -337M -310M -586M -40.16B -595M -4.03B -1.58B -19.63B -1.56B -1.53B -67.67B
Net Debt -980M -858M -794M -730M -1.38B -94.46B -1.4B -9.47B -3.71B -46.18B -3.68B -3.6B -159B -740M -649M -600M -551M -1.04B -71.38B -1.06B -7.16B -2.81B -34.9B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
20/07/26 US$134.15 +0.11% 917,534
17/07/26 US$134.00 -0.06% 1,875,281
16/07/26 US$134.08 -0.16% 1,359,089
15/07/26 US$134.29 +0.25% 607,392
14/07/26 US$133.96 +0.10% 1,365,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.15USD
Average target price
130.53USD
Spread / Average Target
-2.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock